413 related articles for article (PubMed ID: 35387780)
1. Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer.
Revenko A; Carnevalli LS; Sinclair C; Johnson B; Peter A; Taylor M; Hettrick L; Chapman M; Klein S; Solanki A; Gattis D; Watt A; Hughes AM; Magiera L; Kar G; Ireland L; Mele DA; Sah V; Singh M; Walton J; Mairesse M; King M; Edbrooke M; Lyne P; Barry ST; Fawell S; Goldberg FW; MacLeod AR
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35387780
[TBL] [Abstract][Full Text] [Related]
2. Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.
Kashyap AS; Thelemann T; Klar R; Kallert SM; Festag J; Buchi M; Hinterwimmer L; Schell M; Michel S; Jaschinski F; Zippelius A
J Immunother Cancer; 2019 Mar; 7(1):67. PubMed ID: 30871609
[TBL] [Abstract][Full Text] [Related]
3. Foxp3 Silencing with Antisense Oligonucleotide Improves Immunogenicity of an Adjuvanted Recombinant Vaccine against
Batista-Duharte A; Sendra L; Herrero MJ; Portuondo DL; Téllez-Martínez D; Olivera G; Fernández-Delgado M; Javega B; Herrera G; Martínez A; Costa PI; Zeppone Carlos I; Aliño SF
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33801683
[TBL] [Abstract][Full Text] [Related]
4. Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.
Shen L; Ciesielski M; Ramakrishnan S; Miles KM; Ellis L; Sotomayor P; Shrikant P; Fenstermaker R; Pili R
PLoS One; 2012; 7(1):e30815. PubMed ID: 22303460
[TBL] [Abstract][Full Text] [Related]
5. Remodeling of the tumor microenvironment via disrupting Blimp1
Dixon ML; Luo L; Ghosh S; Grimes JM; Leavenworth JD; Leavenworth JW
Mol Cancer; 2021 Nov; 20(1):150. PubMed ID: 34798898
[TBL] [Abstract][Full Text] [Related]
6. Roles of regulatory T cells in cancer immunity.
Takeuchi Y; Nishikawa H
Int Immunol; 2016 Aug; 28(8):401-9. PubMed ID: 27160722
[TBL] [Abstract][Full Text] [Related]
7. Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-α gene therapy for pancreatic cancer.
Aida K; Miyakawa R; Suzuki K; Narumi K; Udagawa T; Yamamoto Y; Chikaraishi T; Yoshida T; Aoki K
Cancer Sci; 2014 Feb; 105(2):159-67. PubMed ID: 24289533
[TBL] [Abstract][Full Text] [Related]
8. Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal.
Isoyama S; Mori S; Sugiyama D; Kojima Y; Tada Y; Shitara K; Hinohara K; Dan S; Nishikawa H
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446575
[TBL] [Abstract][Full Text] [Related]
9. Blockade of TGF-β signaling to enhance the antitumor response is accompanied by dysregulation of the functional activity of CD4
Polanczyk MJ; Walker E; Haley D; Guerrouahen BS; Akporiaye ET
J Transl Med; 2019 Jul; 17(1):219. PubMed ID: 31288845
[TBL] [Abstract][Full Text] [Related]
10. YAP Is Essential for Treg-Mediated Suppression of Antitumor Immunity.
Ni X; Tao J; Barbi J; Chen Q; Park BV; Li Z; Zhang N; Lebid A; Ramaswamy A; Wei P; Zheng Y; Zhang X; Wu X; Vignali P; Yang CP; Li H; Pardoll D; Lu L; Pan D; Pan F
Cancer Discov; 2018 Aug; 8(8):1026-1043. PubMed ID: 29907586
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional regulation of FOXP3 requires integrated activation of both promoter and CNS regions in tumor-induced CD8
Chakraborty S; Panda AK; Bose S; Roy D; Kajal K; Guha D; Sa G
Sci Rep; 2017 May; 7(1):1628. PubMed ID: 28487507
[TBL] [Abstract][Full Text] [Related]
12. CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity.
Zammarchi F; Havenith K; Bertelli F; Vijayakrishnan B; Chivers S; van Berkel PH
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32912922
[TBL] [Abstract][Full Text] [Related]
13. Providence of the CD25
Chakraborty S; Bhattacharjee P; Panda AK; Kajal K; Bose S; Sa G
Immunol Cell Biol; 2018 Nov; 96(10):1035-1048. PubMed ID: 29768737
[TBL] [Abstract][Full Text] [Related]
14. PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells.
Vidotto T; Saggioro FP; Jamaspishvili T; Chesca DL; Picanço de Albuquerque CG; Reis RB; Graham CH; Berman DM; Siemens DR; Squire JA; Koti M
Prostate; 2019 Jun; 79(9):969-979. PubMed ID: 30999388
[TBL] [Abstract][Full Text] [Related]
15. Efficient Therapeutic Function and Mechanisms of Human Polyclonal CD8
Sun J; Yang Y; Huo X; Zhu B; Li Z; Jiang X; Xie R; Gao L; Sun Y; Fan H; Zhu Y; Yang J
J Immunol Res; 2019; 2019():8575407. PubMed ID: 30915372
[TBL] [Abstract][Full Text] [Related]
16. FOXP3/HAT1 Axis Controls Treg Infiltration in the Tumor Microenvironment by Inducing CCR4 Expression in Breast Cancer.
Sarkar T; Dhar S; Chakraborty D; Pati S; Bose S; Panda AK; Basak U; Chakraborty S; Mukherjee S; Guin A; Jana K; Sarkar DK; Sa G
Front Immunol; 2022; 13():740588. PubMed ID: 35222362
[TBL] [Abstract][Full Text] [Related]
17. FoxP3
Saleh R; Elkord E
Cancer Lett; 2020 Oct; 490():174-185. PubMed ID: 32721551
[TBL] [Abstract][Full Text] [Related]
18. [Specific suppression in regulatory T cells by Foxp3 siRNA contributes to enhance the in vitro anti-tumor immune response in hepatocellular carcinoma patients].
Zhang HH; Fei R; Xie XW; Wang L; Luo H; Wang XY; Wei L; Chen HS
Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Jun; 41(3):313-8. PubMed ID: 19727215
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-126 regulates the induction and function of CD4(+) Foxp3(+) regulatory T cells through PI3K/AKT pathway.
Qin A; Wen Z; Zhou Y; Li Y; Li Y; Luo J; Ren T; Xu L
J Cell Mol Med; 2013 Feb; 17(2):252-64. PubMed ID: 23301798
[TBL] [Abstract][Full Text] [Related]
20. Targeting Inhibition of Foxp3 by MMP2/9 Sensitive Short Peptide Linked P60 Fusion Protein 6(P60-MMPs) to Enhance Antitumor Immunity.
Ding X; Peng C; Li Y; Liu J; Song Y; Cai B; Xiang M; Zhang J; Wang Z; Wang L
Macromol Biosci; 2020 Jul; 20(7):e2000098. PubMed ID: 32449306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
